Prelude Capital Management, LLC Savara Inc Transaction History

Prelude Capital Management, LLC

  • $1.57 Billion
  • Q3 2024

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024
BUY
$4.19 - $5.59 $74,494 - $99,384
17,779 New
17,779 $88,000
Q4 2018

Feb 14, 2019
SELL
$6.27 - $10.92 $46,510 - $81,004
-7,418 Closed
0 $0
Q3 2018

Nov 14, 2018
SELL
$10.49 - $12.87 $55,869 - $68,545
-5,326 Reduced 41.79%
7,418 $83,000
Q2 2018

Aug 14, 2018
BUY
$8.55 - $13.76 $108,961 - $175,357
12,744 New
12,744 $144,000

Others Institutions Holding SVRA

# of Institutions
128
Shares Held
158M
Call Options Held
67.6K
Put Options Held
29.4K
View Full List

About Savara Inc

SVRA Quotes by TradingView
  • Ticker SVRA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 114,043,000
  • Market Cap $374M
  • Description
  • Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.
More about SVRA
Track This Portfolio

Track Prelude Capital Management, LLC Portfolio

Follow Prelude Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Prelude Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Prelude Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email